MARKET REPORTS
1 min.Read

United States Chronic Obstructive Pulmonary Disease Market Analysis and Competitive Landscape Report 2022

The “US Chronic Obstructive Pulmonary Disease Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com‘s offering.

The report provides comprehensive insights into Chronic Obstructive Pulmonary Disease pipeline products, Chronic Obstructive Pulmonary Disease epidemiology, Chronic Obstructive Pulmonary Disease market valuations and forecast, Chronic Obstructive Pulmonary Disease drugs sales and competitive landscape in the US.

The research is classified into seven sections – Chronic Obstructive Pulmonary Disease treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.

Research Scope:

  • Chronic Obstructive Pulmonary Disease pipeline: Find out the products in clinical trials for the treatment of Chronic Obstructive Pulmonary Disease by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
  • Chronic Obstructive Pulmonary Disease epidemiology: Find out the number of patients diagnosed (prevalence) with Chronic Obstructive Pulmonary Disease in the US
  • Chronic Obstructive Pulmonary Disease drugs: Identify key products marketed and prescribed for Chronic Obstructive Pulmonary Disease in the US, including trade name, molecule name, and company
  • Chronic Obstructive Pulmonary Disease drugs sales: Find out the sales revenues of Chronic Obstructive Pulmonary Disease drugs in the US
  • Chronic Obstructive Pulmonary Disease market valuations: Find out the market size for Chronic Obstructive Pulmonary Disease drugs in 2021 in the US. Find out how the market advanced from 2019 and forecast to 2027
  • Chronic Obstructive Pulmonary Disease drugs market share: Find out the market shares for key Chronic Obstructive Pulmonary Disease drugs in the US

Benefits of this Research:

  • Support monitoring and reporting national Chronic Obstructive Pulmonary Disease market analysis and sales trends
  • Track competitor drugs sales and market share in the US Chronic Obstructive Pulmonary Disease market
  • Track competitive developments in Chronic Obstructive Pulmonary Disease market and present key issues and learnings
  • Synthesize insights for Chronic Obstructive Pulmonary Disease market and products to drive business performance
  • Answer key business questions about the Chronic Obstructive Pulmonary Disease market
  • Evaluate commercial market opportunity assessment, positioning, and segmentation for Chronic Obstructive Pulmonary Disease products
  • Supports decision making in R&D to long term marketing strategies

For more information about this report visit here.

SourceResearch and Markets

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330